Welcome to Seeking Alpha's Wall Street Breakfast, where we cover the top news for investors

every morning.

Good morning.

Today is Monday, November 3rd, and I'm your host, Kim Kahn, filling in for Julie Morgan.

George Tidmarsh is out as director of the FDA Center for Drug Evaluation and Research,

amid accusations that

he made false statements against Canadian drug maker Orrhenia Pharmaceuticals and disparaged

one of its drugs.

Several outlets reported that Tidmarsh drew Orrhenia's ire for comments on its lupus nephritis

treatment.

In a now deleted post on X, he said the drug, though approved based on surrogate endpoints,

had, quote-unquote, significant toxicity and lacked trials showing benefit on hard clinical outcomes,

like progression to end-stage renal disease.

The Wall Street Journal says Arrhenia filed a federal lawsuit Sunday,

accusing Tidmarsh of making false statements, and soliciting a bribe to get back at Kevin Tang,

Arrini as chairman, and former colleague at La Jolla Pharmaceutical.

Tidmarsh resigned Sunday morning after being placed on administrative leave,

according to an HSS spokeswoman, that he told the New York Times he had not resigned

and called the FDA a toxic environment blaming senior leadership.

He also criticized the agency's new National Priority Review Voucher Program, saying it would

change the entire paradigm of drug approvals without sufficient legal grounding.

Looking to tack, Bidu's Apollo-going unit said fully driverless rides across 250,000 a week,

...